Congress Materials – Anxiety and Depression Association of America (ADAA 2025)
2025 Anxiety and Depression Association of America | Apr 3-5 | Las Vegas, NV
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adult Patients With Treatment-Resistant Depression for up to 4 Months of Treatment: A Post Hoc Analysis
Andrew J. Cutler, Dong-Jing Fu, Ibrahim Turkoz, Mai Himedan, Oliver Lopena, Lisa Lim, John S. Verbanac
Factors Associated With Fulfillment of First Esketamine Prescription Among Patients With Treatment-Resistant Depression in the United States
Terrell D. Holloway, Maryia Zhdanava, Yuxian Du, Aditi Shah, Béatrice Libchaber, Zhuo Chen, Dominic Pilon, Brahim K. Bookhart
Factors Associated with Reaching Remission on Esketamine Among Patients with Treatment-resistant Depression in the United States
Kristin Clemens, Maryia Zhdanava, Arthur Voegel, Anabelle Tardif-Samson, Fengyi Jiang, Dominic Pilon, Yuxian Du
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.